PPM1A is a RelA phosphatase with tumor suppressor-like activity

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Nuclear factor-κB (NF-κB) signaling is implicated in cancer and inflammation.
• RelA phosphorylation at serine residues S536 and S276 is crucial for NF-κB function and oncogenesis.
• Identifying phosphatases that target RelA is key to understanding tumor suppression.

Purpose of the Study:

• To identify and characterize novel RelA phosphatases with tumor-inhibiting activities.
• To investigate the role of PPM1A as a RelA phosphatase and its impact on NF-κB signaling.
• To evaluate PPM1A's potential as a therapeutic target for inhibiting cancer metastasis.

Main Methods:

• Biochemical assays to demonstrate PPM1A's direct dephosphorylation of RelA at S536 and S276.
• Assessment of NF-κB transcriptional activity and downstream cytokine expression (MCP-1, IL-6).
• In vitro cell invasion assays and in vivo mouse models of prostate cancer metastasis.

Main Results:

• PPM1A directly dephosphorylates RelA at S536 and S276, inhibiting NF-κB activity.
• PPM1A expression reduces pro-metastatic cytokine expression and inhibits cancer cell invasion.
• Lower PPM1A expression correlates with metastatic prostate cancer; PPM1A inhibits bone metastasis in mice.

Conclusions:

• PPM1A acts as a RelA phosphatase, suppressing NF-κB signaling and exhibiting tumor suppressor-like activity.
• PPM1A inhibits prostate cancer metastasis, suggesting its therapeutic potential.
• Enhancing PPM1A activity represents a promising strategy to combat NF-κB-driven cancers and bone metastases.